BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRXBiotechnology
+$0.09 today
- Market cap
- $1.88B
- Beta
- 0.56
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.89
Volume 3.78M
Average 4.85M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
Intrinsic Alpha fair value
Locked
Current Price
$7.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -1.7% (5yr)4 analysts |
| Revenue | N/A | N/A | +47.8% | +4.7% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | -1.6% (5yr)6 analysts |
| EBIT | N/A | N/A | N/A | +3.4% (5yr)6 analysts |
Analysis
Recent growth has been strongest in Revenue at +47.8% over three years. Forward estimates point to Revenue at +4.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Pharvaris N.V. NASDAQ:PHVS | $2.34B | $33.36 | Not rated | -11.0 | +30.83% |
Vir Biotechnology, Inc. NASDAQ:VIR | $1.71B | $9.96 | Not rated | -3.0 | +59.53% |
Atea Pharmaceuticals, Inc. NASDAQ:AVIR | $345.31M | $4.30 | Not rated | -2.0 | +31.00% |
Continue the stock analysis
Jump to another research area for this company.